Skip to main content
Log in

Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome

  • Original Article
  • Published:
Journal of Developmental and Physical Disabilities Aims and scope Submit manuscript

Abstract

Fragile X syndrome (FXS) is the most common inherited cause of mental retardation. The behavioral phenotype associated with FXS includes hyperactivity, anxiety, and sometimes problem behaviors for which stimulants, antipsychotics, and SSRI antidepressants are prescribed. Little information, however, is known about the side effects individuals with FXS may experience as a result of taking these medications. Using a nation-wide survey, this study examined the prescription patterns of psychotropic medication use within the FXS population and the prevalence of side effects associated with psychotropic medication use by people diagnosed with FXS. Significant associations were found between the most commonly prescribed medications and side effects for our total sample. These findings give insight to the different dimensions of medication use in people diagnosed with FXS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of Fragile X mental retardation. Trends in Neurosciences, 27, 370–377. doi:10.1016/j.tins.2004.04.009.

    Article  PubMed  Google Scholar 

  • Beckel-Mitchener, A., & Greenough, W. T. (2004). Correlates across the structural, functional, and molecular phenotypes of Fragile X syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 10, 53–59. doi:10.1002/mrdd.20009.

    Article  PubMed  Google Scholar 

  • Berry-Kravis, E. (2002). Epilespsy in Fragile X syndrome. Developmental Medicine and Child Neurology, 44, 724–728. doi:10.1017/S0012162201002833.

    Article  PubMed  Google Scholar 

  • Berry-Kravis, E., & Huttenlocher, P. R. (1992). Cyclic AMP metabolism in Fragile X syndrome. Annals of Neurology, 31, 22–26. doi:10.1002/ana.410310105.

    Article  PubMed  Google Scholar 

  • Berry-Kravis, E., & Potanos, K. (2004). Psychopharmacology in fragile X syndrome--present and future. Mental Retardation and Developmental Disabilities Research Reviews, 10, 42–48.

    Article  PubMed  Google Scholar 

  • Chiurazzi, P., Neri, G., & Oostra, B. A. (2003). Understanding the biological underpinnings of Fragile X syndrome. Current Opinion in Pediatrics, 15, 559–566. doi:10.1097/00008480-200312000-00003.

    Article  PubMed  Google Scholar 

  • Hagerman, R. J. (1997). Fragile X syndrome: molecular and clinical insights and treatment issues. The Western Journal of Medicine, 166, 129–137.

    PubMed  Google Scholar 

  • Hagerman, R. J. (2002a). The physical and behavioral phenotype. In R. J. Hagerman, & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment, and research (pp. 3–109, 3rd ed.). Baltimore, MD: The Johns Hopkins University Press.

    Google Scholar 

  • Hagerman, R. J. (2002b). Medical follow-up and pharmacotherapy. In R. J. Hagerman, & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment, and research (pp. 287–338, 3rd ed.). Baltimore, MD: The Johns Hopkins University Press.

    Google Scholar 

  • Hagerman, R. J., Fulton, M. J., Leaman, A., Riddle, J., Hagerman, K., & Sobesky, W. (1994). A survey of fluoxetine therapy in Fragile X syndrome. Developmental Brain Dysfunction, 7, 155–164.

    Google Scholar 

  • Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988). A controlled trial of stimulant medication in children with the fragile X syndrome. American Journal of Medical Genetics, 30, 377–392. doi:10.1002/ajmg.1320300138.

    Article  PubMed  Google Scholar 

  • Hilton, D. K., Martin, C. A., Heffron, W. M., Hall, B. D., & Johnson, G. L. (1991). Imipramine treatment of ADHD in a fragile X child. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 831–834. doi:10.1097/00004583-199109000-00021.

    Article  PubMed  Google Scholar 

  • Kalachnik, J. E. (1999). Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 348–359. doi:10.1002/(SICI)1098-2779(1999)5:4<348::AID-MRDD13>3.0.CO;2-N.

    Article  Google Scholar 

  • Kaplowitz, M. D., Hadlock, T. D., & Levine, R. (2004). A comparison of web and mail survey response rates. Public Opinion Quarterly, 68, 94–101.

    Article  Google Scholar 

  • Sherman, S. (2002). Epidemiology. In R. J. Hagerman, & P. J. Hagerman (Eds.), Fragile X syndrome: Diagnosis, treatment, and research (pp. 136–168, 3rd ed.). Baltimore, MD: The Johns Hopkins University Press.

    Google Scholar 

  • Tsiouris, J. A., & Brown, W. T. (2004). Neuropsychiatric symptoms of Fragile X syndrome: Pathophysiology and pharmacotherapy. CNS Drugs, 18, 687–703. doi:10.2165/00023210-200418110-00001.

    Article  PubMed  Google Scholar 

  • Valdovinos, M. G., & Kennedy, C. H. (2004). Behavior analytic conceptualization of psychotropic medication side effects. The Behavior Analyst, 27, 231–238.

    Google Scholar 

  • Valdovinos, M. G., & Schroeder, S. R. (2003). The effects of a computerized monitoring system of psychotropic medication use by people with developmental disabilities on staff reported side effects. Journal of Developmental and Physical Disabilities, 15, 299–334. doi:10.1023/A:1026358031999.

    Article  Google Scholar 

  • Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005). Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology, 49, 1053–1066. doi:10.1016/j.neuropharm.2005.06.004.

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

We would like to acknowledge the National Fragile X Foundation for awarding the first author with a Clinical Research Award to support this study and for doing the mailings.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria G. Valdovinos.

Appendix A

Appendix A

Table 8 Current medications
Table 9 Side effects of current medications
Table 10 Past medication use

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valdovinos, M.G., Parsa, R.A. & Alexander, M.L. Results of a Nation-Wide Survey Evaluating Psychotropic Medication Use in Fragile X Syndrome. J Dev Phys Disabil 21, 23–37 (2009). https://doi.org/10.1007/s10882-008-9123-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10882-008-9123-7

Keywords

Navigation